Dr. Kristin Patterson joined SpringWorks Therapeutics in 2018.  She has more than 20 years of pharmaceutical and biotechnology experience with expertise in CMC development, supply chain logistics and commercial manufacture.  Kristin built the CMC function at SpringWorks and continues to play an integral role in defining the manufacturing and CMC regulatory strategy for all assets in development. Previously, Kristin spent 2 years at Mycovia Pharmaceuticals where she led drug product development and manufacturing for multiple anti-fungal assets and 1 year at NephroGenex where she led CMC and CMC regulatory functions.  Kristin spent the first 14 years of her career at GlaxoSmithKline, where she led global, cross-functional teams and provided CMC leadership to development programs from lead optimization to product registration and launch.  During her time at GlaxoSmithKline, she contributed to multiple NDAs and global regulatory filings.  In addition, she spent three years on the Emerging Markets R&D team, which provided a unique opportunity to build her understanding of the development, manufacturing and regulatory requirements needed to expand into these additional geographies. Kristin received her B.S. in Chemistry from the University of Illinois and her Ph.D. in Chemistry from Stanford University.